Of the most senior full time jobs on the career ladder to chief executive, such as divisional or regional heads, only 21% are ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

Kepler Capital analyst David Evans maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) on October 30 and set a price ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of ...

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health agency narrowed the age recommendation for use of RSV vaccines and ...

UnitedHealthcare, an insurer in the United States, offers stand-alone vision insurance or as a “rider” to a United Healthcare dental plan. (Not all vision plans are available in all states.) ...

GSK plc (NYSE:GSK) is a biopharmaceutical company with a long history of driving innovation in developing vaccines, specialty medicines, and general healthcare. The company has important products ...

After completing an investigation into last February's Change Healthcare data breach, the US Department of Health and Human Services confirmed yesterday that 100 million individuals were impacted.

GSK (NYSE:GSK) continued losses for a seventh straight session as the stock closed 0.61% lower, at $37.51 on Friday. The British pharmaceutical company lost 3.13% in the last six trading sessions ...